Clinical trial
ASTERIX: Low Dose ASA and Nexium
NCT00251966 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00251966 |
|---|---|
| Title | ASTERIX: Low Dose ASA and Nexium |
| Official title | A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 mg Once Daily for 26 Weeks. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux |
| Intervention type | Drug |
| Interventions | Esomeprazole |
| Enrollment | 960 |
| Start date | May 1, 2004 |
| Completion | Sep 1, 2005 |
| First posted | Nov 11, 2005 |
| Last update posted | Mar 12, 2009 |
| Countries | Australia, Bulgaria, Canada, Germany, Greece, Hong Kong, Hungary, Italy, South Africa, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: